Concomitant expression of p16INK4a and p14ARF in primary breast cancer and analysis of inactivation mechanisms

Journal of Pathology

Volumn 199, Issue 3, 2003, Pages 289-297

  Silva, Javier ^a   Silva, José M ^a   Domínguez, Gemma ^a   García, José M ^a   Cantos, Blanca ^a   Rodríguez, Rufo ^b   Larrondo, Francisco J ^a   Provencio, Mariano ^a   España, Pilar ^a   Bonilla, Félix ^a  

^a HOSPITAL UNIVERSITARIO PUERTA DE HIERRO   (Spain)

^b HOSPITAL VIRGEN DE LA SALUD   (Spain)

Author keywords

Breast cancer; mRNA expression; p14ARF; p16INK4a; Promoter hypermethylation

Indexed keywords

MESSENGER RNA; PROTEIN P14ARF; PROTEIN P16INK4A; TUMOR SUPPRESSOR PROTEIN; UNCLASSIFIED DRUG;

BREAST CANCER; CONTROLLED STUDY; DNA METHYLATION; DOWN REGULATION; GENE DELETION; GENE INACTIVATION; GENE LOCUS; GENE MUTATION; GENE OVEREXPRESSION; GENE SILENCING; GENETIC CODE; HEMIZYGOSITY; HUMAN; HUMAN CELL; HUMAN TISSUE; PATHOGENESIS; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; REVIEW; TUMOR CELL;

BREAST NEOPLASMS; CYCLIN-DEPENDENT KINASE INHIBITOR P16; DNA METHYLATION; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE SILENCING; GENES, P16; HUMANS; LOSS OF HETEROZYGOSITY; NEOPLASM PROTEINS; POLYMERASE CHAIN REACTION; PROMOTER REGIONS (GENETICS); REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; RNA, NEOPLASM; TUMOR SUPPRESSOR PROTEIN P14ARF;

EID: 0037372014     PISSN: 00223417     EISSN: None     Source Type: Journal    
DOI: 10.1002/path.1297     Document Type: Review

References (66)

1. Sherr CJ. Cancer cell cycles. Science 1996; 274: 1672-1677.
2. Sherr CJ. Tumor surveillance via the ARF-p53 pathway. Genes Dev 1998; 12: 2984-2991.
3. Serrano M, Hannon GJ, Beach D. A new regulatory motif in cell-cycle control causing specific inhibition of cyclin D/CDK4. Nature 1993; 366: 704-707.
4. Zhang HS, Postigo AA, Dean DC. Active transcriptional repression by the Rb-E2F complex mediates G1 arrest triggered by p16INK4a, TGFbeta, and contact inhibition. Cell 1999; 97: 53-61.
5. Quelle DE, Zindy F, Ashmun RA, Sherr CJ. Alternative reading frames of the INK4a tumor suppressor gene encode two unrelated proteins capable of inducing cell cycle arrest. Cell 1995; 83: 993-1000.
6. INK4a/MTS1 gene transcript expressed in B-cell malignancies. Oncogene 1995; 11: 21-29.
7. INK4a transcript. Cancer Res 1995; 55: 2995-2997.
8. Stone S, Jiang P, Dayananth P, et al. Complex structure and regulation of the p16 (MTS1) locus. Cancer Res 1995; 55: 2988-2994.
9. Quelle DE, Zindy F, Ashmun RA, Sherr CJ. Alternative reading frames of the INK4a tumor suppressor gene encode two unrelated proteins capable of inducing cell cycle arrest. Cell 1995; 83: 993-1000.
10. Liggett WH, Sewell DA, Rocco J, Ahrendt SA, Koch W, Sidransky D. p16 and p16β are potent growth suppressors of head and neck squamous carcinoma cells in vitro. Cancer Res 1996; 56: 4119-4123.
11. ARF stabilizes p53 by blocking nucleocytoplasmic shuttling of Mdm2. Proc Natl Acad Sci U S A 1999; 96: 6937-6941.
12. Zhang Y, Xiong Y, Yarbrough WG. ARF promotes MDM2 degradation and stabilizes p53. ARF-INK4a locus deletion impairs both the Rb and p53 tumor suppression pathways. Cell 1998; 92: 725-734.
13. ARF, interacts with MDM2 and neutralizes MDM2's inhibition of p53. Cell 1998; 92: 713-723.
14. Kamijo T, Weber JD, Zambetti G, Zindy F, Roussel MF, Sherr CJ. Functional and physical interactions of the ARF tumor suppressor with p53 and Mdm2. Proc Natl Acad Sci U S A 1998; 95: 8292-8297.
15. Cairns P, Poladcik TJ, Eby Y, et al. Frequency of homozygous deletion at p16/CDKN2 in primary human tumors. Nature Genet 1995; 11: 210-212.
16. Jen J, Harper JW, Bigner SH, et al. Deletion of p16 and p15 genes in brain tumors. Cancer Res 1994; 54: 6353-6358.
17. Cheng JQ, Jhanwar SC, Klein WM, et al. p16 alterations and deletion mapping of 9p21-22 in malignant mesotheliomas. Cancer Res 1994; 54: 5547-5551.
18. INK4B ) display frequent homozygous deletion in primary cells from T- but not B-cell lineage acute lymphoblastic leukemias. Blood 1994; 84: 4038-4044.
19. Ohta M, Nagai H, Shimizu M, et al. Rarity of somatic and germline mutations of the cyclin-dependent kinase 4 inhibitor gene, CDK4I, in melanoma. Cancer Res 1994; 54: 5269-5272.
20. Schultz DC, Vanderveer L, Buetow KH, et al. Characterization of chromosome 9 in human ovarian neoplasia identifies frequent genetic imbalance on 9q and rare alterations involving 9p, including CDKN2. Cancer Res 1995; 55: 2150-2157.
21. Maelandsmo GM, Berner J-M, Florenes VA, et al. Homozygous deletion frequency and expression levels of the CDKN2 gene in human sarcomas - relationship to amplification and mRNA levels of CDK4 and CCND1. Br J Cancer 1995; 72: 393-398.
22. Maesawa C, Tamura G, Nishizuka S, et al. Inactivation of the CDKN2 gene by homozygous deletion and de novo methylation is associated with advanced stage esophageal squamous cell carcinomas. Cancer Res 1996; 56: 3875-3878.
23. Costello JF, Berger MS, Huang H-J, Cavenee WK. Silencing of p16/CDKN2 expression in human gliomas by methylation and chromatin condensation. Cancer Res 1996; 56: 2405-2410.
24. Gonzalez-Zulueta M, Bender CM, Yang AS, et al. Methylation of the 5′ CpG island of the p16/CDKN2 tumor suppressor gene in normal and transformed human tissues correlates with gene silencing. Cancer Res 1995; 55: 4531-4535.
25. Woodwock DM, Linsenmeyer ME, Doherty JP, Warren WD. DNA methylation in the promoter region of the p16 (CDKN2/MTS-1/INK4A) gene in human breast tumours. Br J Cancer 1999; 79: 251-256.
26. INK4a messenger RNA is a marker of poor prognosis. Clin Cancer Res 2000; 6: 2777-2787.
27. Nielsen NH, Roos G, Emdin SO, Landberg G. Methylation of the p16(Ink4a) tumor suppressor gene 5′-CpG island in breast cancer. Cancer Lett 2001; 163: 59-69.
28. Esteller M, Fraga MF, Guo M, et al. DNA methylation patterns in hereditary human cancers mimic sporadic tumorigenesis. Hum Mol Genet 2001; 26: 3001-3007.
29. Herman JG, Merlo A, Mao L, et al. Inactivation of the CDKN2/p16/MTS1 gene is frequently associated with aberrant DNA methylation in all common human cancers. Cancer Res 1995; 55: 4525-4530.
30. CDKN2 inactivation in non-small cell lung cancer lines. Cancer Res 1995; 55: 6200-6209.
31. Merlo A, Herman JG, Mao L, et al. 5′ CpG island methylation is associated with transcriptional silencing of the tumor suppressor CDKN2/p16 in human cancers. Nature Med 1995; 7: 686-692.
32. Markl IDC, Jones PA. Presence and location of TP53 mutation determines pattern of CDKN2/ARF pathway inactivation in bladder cancer. Cancer Res 1998; 58: 5348-5353.
33. Orlow I, LaRue H, Osnam I, et al. Deletions of the INK4a gene in superficial bladder tumors. Association with recurrence. Am J Pathol 1999; 155: 105-113.
34. Sanchez-Cespedes M, Reed AL, Buta M, et al. Inactivation of the INK4a/ARF locus frequently coexists with TP53 mutations in non-small cell lung cancer. Oncogene 1999; 18: 5843-5849.
35. Newcomb EW, Alonso M, Sung T, Miller DC. Incidence of p14ARF gene deletion in high grade adult and pediatric astrocytomas. Hum Pathol 2000; 31: 115-119.
36. Iwato M, Tachibana O, Tohma Y, et al. Alteration of the INK4a/ARF locus in human intracranial germ cell tumors. Cancer Res 2000; 60: 2113-2115.
37. Sarkar S, Julicher KP, Burger MS, et al. Different combinations of genetic/epigenetic alterations inactivate the p53 and pRb pathways in invasive human bladder cancers. Cancer Res 2000; 60: 3862-3871.
38. Fulci G, Labuhn M, Maier D, et al. p53 gene mutation and ink4a-arf deletion appear to be two mutually exclusive events in human glioblastoma. Oncogene 2000; 19: 3816-3822.
39. Randerson-Moor JA, Harland M, Williams S, et al. A germline deletion of p14(ARF) but not CDKN2A in a melanoma-neural system tumour syndrome family. Hum Mol Genet 2001; 10: 55-62.
40. INK4a methylation and p53 mutational status. Cancer Res 2000; 60: 129-133.
41. Zheng S, Chen P, McMillan A, et al. Correlations of partial and extensive methylation at the p14(ARF) locus with reduced mRNA expression in colorectal cancer cell lines and clinicopathological features in primary tumors. Carcinogenesis 2000; 21: 2057-2064.
42. Iida S, Akiyama Y, Nakajima T, et al. Alterations and hypermethylation of the p14(ARF) gene in gastric cancer. Int J Cancer 2000; 87: 654-658.
43. Zochbauer-Muller S, Fong KM, Virmani AK, Geradts J, Gazdar AF, Minna JD. Aberrant promoter methylation of multiple genes in non-small cell lung cancers. Cancer Res 2001; 61: 249-255.
44. INK4a gene is frequently lost in small cell lung cancer. Cancer Res 1998; 58: 3926-3931.
45. Vonlanthen S, Heighway J, Tschan MP, et al. Expression of p16INK4a/p16α and p19ARF/p16β is frequently altered in non-small cell lung cancer and correlates with p53 overexpression. Oncogene 1998; 17: 2779-2785.
46. Brenner AJ, Paladugu A, Wang H, Olopade OI, Dreyling MH, Aldaz CM. Preferential loss of expression of p16(INK4a) rather than p19(ARF) in breast cancer. Clin Cancer Res 1996; 2: 1993-1998.
47. Herranz M, Urioste M, Santos J, et al. Analysis of the INK4a/ARF locus in non-Hodgkin's lymphomas using two internal microsatellite markers. Leukemia 1999; 13: 808-810.
48. Pinyol M, Hernandez L, Martinez A, et al. INK4a/ARF locus alterations in human non-Hodgkin's lymphomas mainly occur in tumors with wild-type p53 gene. Am J Pathol 2000; 56: 1987-1996.
49. Taniguchi T, Chikatsu N, Takahashi S, et al. Expression of p16INK4A and p14ARF in hematological malignancies. Leukemia 1999; 13: 1760-1769.
50. Melendez B, Malumbres M, de Castro IP, Santos J, Pellicer A, Fernandez-Piqueras J. Characterization of the murine p19(ARF) promoter Cp island and its methylation pattern in primary lymphomas. Carcinogenesis 2000; 21: 817-821.
51. Pabst T, Peters UR, Tinguely M, et al. Divergent expression of the cyclin-dependent kinase inhibitors (Cki) and p14arf/p16beta in non-Hodgkin's lymphomas and chronic lymphocytic leukemia. Leuk Lymphoma 2000; 37: 639-648.
52. Takemoto S, Trovato R, Cereseto A, et al. p53 stabilization and functional impairment in the absence of genetic mutation or the alteration of the p14(ARF)-MDM2 loop in ex vivo and cultured adult T-cell leukemia/lymphoma cells. Blood 2000; 95: 3939-3944.
53. Faderl S, Kantarjian HM, Estey E, et al. The prognostic significance of p16(INK4a)/p14(ARF) locus deletion and MDM-2 protein expression in adult acute myelogenous leukemia. Cancer 2000; 89: 1976-1982.
54. Silva J, Dominguez G, Silva JM, et al. Analysis of genetic and epigenetic processes that influence p14ARF expression in breast cancer. Oncogene 2001; 20: 4586-4590.
55. Oto M, Miyake S, Yuasa Y. Optimization of nonradioisotopic single strand conformation polymorphism analysis with a conventional minislab gel electrophoresis apparatus. Ann Biochem 1993; 213: 19-22.
56. Herman JG, Graff JR, Myöhänen S, Nelkin BD, Baylin SB. Methylation-specific PCR: a novel PCR assay for methylation status of CpG islands. Proc Natl Acad Sci U S A 1996; 93: 9821-9826.
57. Mai M, Yokomizo A, Qian C, et al. Activation of p73 silent allele in lung cancer. Cancer Res 1998; 58: 2347-2349.
58. Bird A. The essential of the DNA methylation. Cell 1992; 70: 5-8.
59. Robertson KD, Jones PA. The human ARF cell cycle regulatory gene promoter is a CpG island which can be silenced by DNA methylation and downregulated by wild type p53. Mol Cell Biol 1998; 18: 6457-6473.
60. Stone S, Jiang P, Dayananth P, et al. Complex structure and regulation of the p16(MTS1) locus. Cancer Res 1995; 55: 2988-2994.
61. Rocco JW, Sidransky D. p16(MTS-1/CDKN2/INK4a) in cancer progression. Exp Cell Res 2001; 264: 42-55.
62. ARF, and CDK4 in familial melanoma: analysis of a clinic-based population. Proc Natl Acad Sci U S A 1996; 93: 8541-8545.
63. Zindy F, Eischen CM, Randle D, et al. Myc signaling via the ARF tumor suppressor regulates p53-dependent apoptosis and immortalization. Genes Dev 1998; 12: 2424-2434.
64. ARF tumor suppressor. Genes Dev 1998; 12: 2435-2443.
65. Sidransky D. Two tracks but one race? Cancer genetics. Curr Biol 1996; 6: 523-525.
66. Sharpless NE, De Pinho RA. The INK4A/ARF locus and its two gene products. Curr Opin Genet Dev 1999; 9: 22-30.